Credit Suisse analysts predict Allergan's Vraylar could hit $1.16 billion in sales by 2026. (Allergan) Allergan, badly in need of good news, finally has some to ...

Tocagen said Tuesday its brain cancer trial has not been able to show so far that a combination therapy of experimental agents Toca 511 and Toca FC extended survi...

A phase 3 clinical trial testing esketamine nasal spray in the treatment of severe depression found the spray mostly safe and effective. The findings led to the rece...

A small North Carolina-based biotech got a lot smaller Tuesday, despite the company announcing its rare disease drug met the primary goal of a pivotal Phase 3 stu...

The Medicines Company on Saturday released data from a long-term safety study of its experimental cholesterol-lowering drug inclisiran in heart disease patients, ...

Array's Mektovi and Braftovi, when combined with Erbitux, produced a survival benefit in patients with BRAF-positive colon cancer. (Array BioPharma) The news tha...

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, accord...

An experimental immunology drug from Eli Lilly has scored positive data in a mid-stage study of Crohn's disease patients.The study enrolled 180 participants, who rec...